LXRX vs. CLDX, INVA, NVAX, DVAX, MNKD, OPK, GERN, RIGL, ZBIO, and VSTM
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs. Its Competitors
Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
Lexicon Pharmaceuticals has a net margin of -206.43% compared to Celldex Therapeutics' net margin of -3,446.88%. Celldex Therapeutics' return on equity of -27.61% beat Lexicon Pharmaceuticals' return on equity.
Lexicon Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
In the previous week, Celldex Therapeutics had 10 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 13 mentions for Celldex Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.95 beat Lexicon Pharmaceuticals' score of 0.73 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Celldex Therapeutics has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 13.9% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Lexicon Pharmaceuticals currently has a consensus target price of $3.23, indicating a potential upside of 180.43%. Celldex Therapeutics has a consensus target price of $46.67, indicating a potential upside of 108.52%. Given Lexicon Pharmaceuticals' higher possible upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.
Summary
Celldex Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access